[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2010002769A - Preparacion recombinante de fracciones de bromelaina seleccionadas. - Google Patents

Preparacion recombinante de fracciones de bromelaina seleccionadas.

Info

Publication number
MX2010002769A
MX2010002769A MX2010002769A MX2010002769A MX2010002769A MX 2010002769 A MX2010002769 A MX 2010002769A MX 2010002769 A MX2010002769 A MX 2010002769A MX 2010002769 A MX2010002769 A MX 2010002769A MX 2010002769 A MX2010002769 A MX 2010002769A
Authority
MX
Mexico
Prior art keywords
bromelain
recombinant preparation
found
fractions
present
Prior art date
Application number
MX2010002769A
Other languages
English (en)
Inventor
Rolf Mueller
Nora Luniak
Klaus Eschmann
Original Assignee
Ursapharm Arzneimittel Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ursapharm Arzneimittel Gmbh filed Critical Ursapharm Arzneimittel Gmbh
Publication of MX2010002769A publication Critical patent/MX2010002769A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/63—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Botany (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)

Abstract

La presente invención se refiere en general a bromelaína y particularmente a los compuestos activos diferentes contenidos en esta mezcla compleja de proteínas. La presente invención proporciona cisteína proteasas expresadas recombinantes, las cuales se encuentran en la bromelaína. Se ha encontrado que el método para la expresión de proteínas recombinantes es superior a la purificación propia de bromelaína.
MX2010002769A 2007-09-14 2008-08-08 Preparacion recombinante de fracciones de bromelaina seleccionadas. MX2010002769A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07018125A EP2036978A1 (en) 2007-09-14 2007-09-14 Recombinant preparation of selected bromelain fractions
PCT/EP2008/006564 WO2009033536A1 (en) 2007-09-14 2008-08-08 Recombinant preparation of selected bromelain fractions

Publications (1)

Publication Number Publication Date
MX2010002769A true MX2010002769A (es) 2010-09-07

Family

ID=39144517

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002769A MX2010002769A (es) 2007-09-14 2008-08-08 Preparacion recombinante de fracciones de bromelaina seleccionadas.

Country Status (11)

Country Link
US (1) US8409840B2 (es)
EP (2) EP2036978A1 (es)
JP (1) JP2010538622A (es)
CN (1) CN101889083A (es)
CA (1) CA2699429A1 (es)
DK (1) DK2173868T3 (es)
ES (1) ES2395591T3 (es)
MX (1) MX2010002769A (es)
PL (1) PL2173868T3 (es)
PT (1) PT2173868E (es)
WO (1) WO2009033536A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL165334A0 (en) 2004-11-22 2006-01-15 Mediwound Ltd Debriding composition from bromelain and methods of producing same
MY190244A (en) * 2009-12-17 2022-04-08 International Islamic Univ Malaysia Method for producing recombinant stem bromelain
EP2831099B1 (en) 2012-03-26 2020-04-22 Axcella Health Inc. Nutritive fragments, proteins and methods
JP2015518470A (ja) 2012-03-26 2015-07-02 プロニュートリア・インコーポレイテッドＰｒｏｎｕｔｒｉａ， Ｉｎｃ． 栄養タンパク質および方法
SG11201405842PA (en) 2012-03-26 2014-10-30 Pronutria Inc Charged nutritive proteins and methods
WO2013148325A1 (en) 2012-03-26 2013-10-03 Pronutria, Inc. Nutritive fragments, proteins and methods
US9878004B2 (en) 2013-09-25 2018-01-30 Axcella Health Inc. Compositions and formulations for treatment of gastrointestinal tract malabsorption diseases and inflammatory conditions and methods of production and use thereof
RU2732224C9 (ru) 2016-01-31 2021-06-18 Медивунд Лтд. Раноочищающая композиция для лечения ран
JP6859158B2 (ja) * 2017-03-31 2021-04-14 第一工業製薬株式会社 ポリウレタン樹脂用ポリオール組成物、ポリウレタン樹脂形成性組成物、複合材料
CN110477100B (zh) * 2019-08-22 2023-11-07 内蒙古蒙牛乳业（集团）股份有限公司 一种两吃型酸奶固体饮料及其制备方法
WO2021255625A1 (en) * 2020-06-16 2021-12-23 Anatara Lifesciences Limited Protease composition
WO2024209443A1 (en) * 2023-04-07 2024-10-10 Neilos S.r.l. Nutraceutical or pharmaceutical composition comprising bromelain

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3658651A (en) * 1970-04-28 1972-04-25 Castle & Cooke Ion exchange treatment of bromelain
US4286064A (en) * 1979-11-05 1981-08-25 Riker Laboratories, Inc. Process for isolating active debriding agent from bromelain
GB9313188D0 (en) * 1993-06-25 1993-08-11 Cortecs Ltd Medical use of enzymes
KR100201008B1 (ko) * 1996-10-09 1999-06-15 박종헌 글루텐 펩타이드를 외인성 고지혈증 및 고콜레스트레롤증 억제에 이용하는 방법
CN1091152C (zh) 1996-12-23 2002-09-18 茂名市茂辉公司化州分公司 菠萝蛋白酶的物理提取方法
JP2001513636A (ja) * 1997-02-25 2001-09-04 コルテクス（ユーケイ）リミティッド ブロメラインの成分
PT1096951E (pt) * 1998-07-15 2003-01-31 Ursapharm Arzneimittel Gmbh Utilizacao de proteases de bromelaina para a preparacao de um medicamento para a inibicao de coagulacao do sangue
GB9819138D0 (en) * 1998-09-02 1998-10-28 Cortecs Uk Ltd Nucleic acids and proteins from pineapple stem
JP2002003362A (ja) * 2000-06-22 2002-01-09 Kyoei Kagaku Kogyo Kk 皮膚外用剤
JP4969741B2 (ja) * 2001-07-26 2012-07-04 株式会社ノエビア 皮膚外用剤
WO2005096804A2 (en) * 2004-03-08 2005-10-20 Syngenta Participations Ag Self-processing plants and plant parts
DE602004025192D1 (de) * 2003-12-05 2010-03-11 Roche Diagnostics Gmbh Rekombinante Carboxypeptidase B und ihre Aufreinigung
EP2048939A4 (en) * 2006-08-17 2010-04-28 Monsanto Technology Llc TRANSGENIC PLANTS WITH ADVANCED AGRONOMIC CHARACTERISTICS

Also Published As

Publication number Publication date
PT2173868E (pt) 2013-01-08
WO2009033536A1 (en) 2009-03-19
CN101889083A (zh) 2010-11-17
DK2173868T3 (da) 2013-02-18
JP2010538622A (ja) 2010-12-16
ES2395591T3 (es) 2013-02-13
US20100272659A1 (en) 2010-10-28
EP2173868A1 (en) 2010-04-14
PL2173868T3 (pl) 2013-03-29
CA2699429A1 (en) 2009-03-19
EP2173868B1 (en) 2012-10-17
US8409840B2 (en) 2013-04-02
EP2036978A1 (en) 2009-03-18

Similar Documents

Publication Publication Date Title
MX2010002769A (es) Preparacion recombinante de fracciones de bromelaina seleccionadas.
MX339402B (es) Composiciones y metodos que comprenden variantes de serina proteasa.
MY145081A (en) Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
EA200801531A1 (ru) Способы регулирования содержания маннозы в рекомбинантных белках
MY159396A (en) Compositions and methods for antibodies targeting complement protein c5
MY168961A (en) Antibodies to pcsk9 and uses thereof
TW200602037A (en) Novel compounds as inhibitors of hepatitis C virus NS3 serine protease
MY161617A (en) Removal of serine proteases by treatment with finely divided silicon dioxide
MX351414B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
MX2011013455A (es) Diseño de moleculas de fc de anticuerpo estables y libres de agregacion a traves del diseño de la interfase del dominio de ch3.
WO2008124148A3 (en) Sulfur compounds as inhiibitors of hepatitis c virus ns3 serine protease
EA201391157A1 (ru) Антагонисты pcsk9
MX2012007684A (es) Modificacion covalente ligando dirigida de proteina.
MX2009010207A (es) Peptidos de hidrazido como inhibidores de proteasa ns3 de virus de hepatitis c.
MX2009010148A (es) Peptidos ciclicos de proteinas receptor-asociadas (rap).
MX2011011272A (es) Procesos e intermediarios.
MX2010004704A (es) Inhibidores macrociclicos de la ns3 serina proteasa del virus de la hepatitis c.
MX2009010205A (es) Inhibidores de cetoamida p1-no epimerizables de proteasa ns3 de virus de hepatitis c.
MX2008011872A (es) Analogos de tiazolidinediona para el tratamiento de la hipertension y para disminuir lipidos.
EP2195331A4 (en) SYNTHETIC APOLIPOPROTEIN RECIPIENTS AND METHOD OF USE
EP1963506A4 (en) COMPOSITIONS AND METHODS FOR INCREASING THE PRODUCTION OF RECOMBINANT GAMMA-CARBOXYLATED PROTEINS
TW200700057A (en) Alpha ketoamide compounds as cysteine protease inhibitors
PH12014501200A1 (en) Bacteriophage gene 3 protein compositions and use as amyloid binding agents
WO2011069037A3 (en) Stabilization and storage of biological pharmaceutical compositions
MX2007011739A (es) Compuestos que contienen sulfonilo como inhibidores de cisteina proteasa.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal